Stone, R. M., Allen, S. L., Pigneux, A., Stuart, R. K., Wetzler, M., Rizzieri, D., … Powell, B. L. (2011). A phase III, open-label, randomized comparison of AS1413 (amonafide L-malate) plus cytarabine with daunorubicin plus cytarabine in secondary acute myeloid leukemia (ACCEDE). In Journal of Clinical Oncology (Vol. 29, pp. 6520–6520). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2011.29.15_suppl.6520

Stone, R. M., S. L. Allen, A. Pigneux, R. K. Stuart, M. Wetzler, D. Rizzieri, H. P. Erba, et al. “A phase III, open-label, randomized comparison of AS1413 (amonafide L-malate) plus cytarabine with daunorubicin plus cytarabine in secondary acute myeloid leukemia (ACCEDE).” In Journal of Clinical Oncology, 29:6520–6520. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.6520.

Stone RM, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, et al. A phase III, open-label, randomized comparison of AS1413 (amonafide L-malate) plus cytarabine with daunorubicin plus cytarabine in secondary acute myeloid leukemia (ACCEDE). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011. p. 6520–6520.

Stone, R. M., et al. “A phase III, open-label, randomized comparison of AS1413 (amonafide L-malate) plus cytarabine with daunorubicin plus cytarabine in secondary acute myeloid leukemia (ACCEDE).” Journal of Clinical Oncology, vol. 29, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2011, pp. 6520–6520. Crossref, doi:10.1200/jco.2011.29.15_suppl.6520.

Stone RM, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon LE, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, Miklos E, Horst H, Selleslag DLD, Solomon SR, Venugopal P, Lundberg AS, Powell BL. A phase III, open-label, randomized comparison of AS1413 (amonafide L-malate) plus cytarabine with daunorubicin plus cytarabine in secondary acute myeloid leukemia (ACCEDE). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011. p. 6520–6520.